SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
ATLANTA, Sept. 07, 2016 -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that Aviragen's CEO & President Joseph Patti, PhD will present a corporate overview at the following upcoming conferences:
- Rodman & Renshaw 18th Annual Global Investment Conference at 4:15 p.m. ET on Tuesday, September 13, 2016 in New York, NY. Link: http://wsw.com/webcast/rrshq26/avir
- Ladenburg Thalmann 2016 Healthcare Conference at 2:30 p.m. ET on Tuesday, September 27, 2016 in New York, NY. Link: http://wsw.com/webcast/ladenburg2/avir
A live audio webcast of each presentation can be accessed under “Events and Presentations” in the Investors section of the Company’s website at www.aviragentherapeutics.com. An archived replay of the webcast will be available for 30 days after the live event concludes.
About Aviragen Therapeutics, Inc.
Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: These include vapendavir, an oral treatment for human rhinovirus upper (HRV) respiratory infections in moderate-to-severe asthmatics currently being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor that has received Fast Track designation by the U.S. FDA, in Phase 2 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.aviragentherapeutics.com.
Contacts: Mark Colonnese Executive Vice President and Chief Financial Officer Aviragen Therapeutics, Inc. (678) 221-3381 [email protected] Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
